Kazuyuki Matsushita


Affiliation: Chiba University
Country: Japan


  1. Suzuki Y, Matsushita K, Seimiya M, Yoshida T, Sawabe Y, Ogawa M, et al. Paradoxical effects of thyroid function on glomerular filtration rate estimated from serum creatinine or standardized cystatin C in patients with Japanese Graves' disease. Clin Chim Acta. 2015;451:316-22 pubmed publisher
    ..Renal function evaluation by eGFRCr and eGFRCysC had clinical utility in post-treatment euthyroidism. ..
  2. Semba T, Nishimura M, Nishimura S, Ohara O, Ishige T, Ohno S, et al. The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis. BMC Gastroenterol. 2013;13:120 pubmed publisher
    ..Overexpression and distinct localization of LCN2, CXCL1 and CXCL9 in the liver of fatty liver Shionogi mice suggest significant roles of these proteins in the pathogenesis of NASH. ..
  3. Tonoike Y, Matsushita K, Tomonaga T, Katada K, Tanaka N, Shimada H, et al. Adhesion molecule periplakin is involved in cellular movement and attachment in pharyngeal squamous cancer cells. BMC Cell Biol. 2011;12:41 pubmed publisher
    ..PPL knockdown is related to reduced cellular movement and attachment activity in association with PI3K/Akt axis suppression, rather than malignant progression in pharyngeal cancer cells. ..
  4. Matsushita K, Takenouchi T, Shimada H, Tomonaga T, Hayashi H, Shioya A, et al. Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: Possible involvement of c-myc suppression by interferon-gamma in situ. Cancer Sci. 2006;97:57-63 pubmed
  5. Matsushita K, Tomonaga T, Kajiwara T, Shimada H, Itoga S, Hiwasa T, et al. c-myc suppressor FBP-interacting repressor for cancer diagnosis and therapy. Front Biosci (Landmark Ed). 2009;14:3401-8 pubmed
    ..Together, one clue to the development of cancer diagnosis and therapies directed against c-Myc may go through FIR and its splicing variant. ..
  6. Matsushita K, Kajiwara T, Tamura M, Satoh M, Tanaka N, Tomonaga T, et al. SAP155-mediated splicing of FUSE-binding protein-interacting repressor serves as a molecular switch for c-myc gene expression. Mol Cancer Res. 2012;10:787-99 pubmed publisher
    ..In conclusion, altered FIR and c-myc pre-mRNA splicing, in addition to c-Myc expression by augmented FIR/FIR?exon2-SAP155 complex, potentially contribute to colorectal cancer development. ..
  7. Matsushita K, Tamura M, Tanaka N, Tomonaga T, Matsubara H, Shimada H, et al. Interactions between SAP155 and FUSE-binding protein-interacting repressor bridges c-Myc and P27Kip1 expression. Mol Cancer Res. 2013;11:689-98 pubmed publisher